AU2003231252A1 - Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease - Google Patents
Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's diseaseInfo
- Publication number
- AU2003231252A1 AU2003231252A1 AU2003231252A AU2003231252A AU2003231252A1 AU 2003231252 A1 AU2003231252 A1 AU 2003231252A1 AU 2003231252 A AU2003231252 A AU 2003231252A AU 2003231252 A AU2003231252 A AU 2003231252A AU 2003231252 A1 AU2003231252 A1 AU 2003231252A1
- Authority
- AU
- Australia
- Prior art keywords
- alzheimer
- disease
- prevention
- compositions
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37968402P | 2002-05-09 | 2002-05-09 | |
US60/379,684 | 2002-05-09 | ||
PCT/US2003/013689 WO2003094909A2 (en) | 2002-05-09 | 2003-05-02 | Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003231252A1 true AU2003231252A1 (en) | 2003-11-11 |
Family
ID=29420551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003231252A Abandoned AU2003231252A1 (en) | 2002-05-09 | 2003-05-02 | Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003231252A1 (en) |
WO (1) | WO2003094909A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20110235A1 (en) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE |
MX2008014024A (en) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Polymorphs. |
PE20140960A1 (en) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | FORMULATIONS INVOLVING A DPP4 INHIBITOR |
UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
KR20200118243A (en) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Treatment for diabetes in patients inappropriate for metformin therapy |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
WO2010072776A1 (en) | 2008-12-23 | 2010-07-01 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
AR074990A1 (en) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY |
CN102753161A (en) | 2009-11-27 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
ES2935300T3 (en) | 2010-05-05 | 2023-03-03 | Boehringer Ingelheim Int | combitherapy |
CN106975074A (en) | 2010-06-24 | 2017-07-25 | 勃林格殷格翰国际有限公司 | Treating diabetes |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
WO2013010964A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US20140100236A1 (en) * | 2012-10-09 | 2014-04-10 | Boehringer Ingelheim International Gmbh | Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
BR112018072401A2 (en) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinations of linagliptin and metformin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997048701A1 (en) * | 1996-06-20 | 1997-12-24 | Pfizer Inc. | 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors |
-
2003
- 2003-05-02 AU AU2003231252A patent/AU2003231252A1/en not_active Abandoned
- 2003-05-02 WO PCT/US2003/013689 patent/WO2003094909A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2003094909A3 (en) | 2004-04-01 |
WO2003094909A2 (en) | 2003-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003231252A1 (en) | Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease | |
EP1392287B8 (en) | Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease | |
WO2003072035A8 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004041170A9 (en) | Compositions and methods for the treatment of immune related diseases | |
AU2003220096A1 (en) | Methods for alzheimer's disease treatment and cognitive enhancement | |
AU2003206413A1 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
WO2004024097A9 (en) | Compositions and methods for the treatment of immune related diseases | |
AU2002243023A1 (en) | Compositions for preventing and/or treating oral diseases | |
IL158181A0 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
PL371281A1 (en) | Methods and compositions for the treatment of eye diseases | |
AU2003303141A1 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
AU2003273310A1 (en) | Substituted aminoethers for the treatment of alzheimer's disease | |
AU2003248660A1 (en) | Treatment of vascular dysfunction and alzheimer's disease | |
AU4228000A (en) | Methods and compositions for the treatment and prevention of lung disease | |
PL377110A1 (en) | Prevention and treatment of alzheimer's disease | |
AU2003248893A8 (en) | Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias | |
AU2003299101A1 (en) | Compounds for the treatment of alzheimer's disease | |
AU4225500A (en) | Methods and compositions for the treatment and prevention of lung disease | |
GB0201025D0 (en) | The treatment of degenerative diseases | |
AU2003230848A1 (en) | Methods and compositions for treating alzheimer's disease | |
AU2003289889A1 (en) | Methods for the treatment of alzheimers disease and compositions therefore | |
AU2003286530A1 (en) | Substituted peptides useful in the treatment of alzheimer's disease | |
AU2002348324A1 (en) | Methods and compositions for the treatment and diagnosis of pain disorders using 46566 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase | ||
TH | Corrigenda |
Free format text: IN VOL 18, NO 2, PAGE(S) 509 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME ENOS PHARMACEUTICALS, INC., APPLICATION NO. 2003231252, UNDER INID(43) CORRECT THE PUBLICATION DATE TO READ 24.11.2003 |